Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Can serological markers such as KL-6, MMP-7, and anti-CarP be used to monitor interstitial lung disease in patients with rheumatoid arthritis in clinical practice?
Related Questions
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
How do you approach management of patients with RA who have paradoxical eczematous reaction while on TNF inhibitor?
How can we approach tapering or discontinuing biologic DMARDs in patient in their 80s with well controlled rheumatoid arthritis?
How do you approach diagnosis in a patient with inflammatory joint symptoms and isolated bilateral CMC joint erosions on x-ray imaging?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
Would you consider prescribing a JAK inhibitor for a patient with a history of DVT who is on chronic anticoagulation, or would the thrombotic risk deter you?
How would you manage a patient with RA with newly diagnosed T-LGLL who was previously treated with Enbrel and is now flaring off Enbrel while on low dose methotrexate?
Is cimzia an option for patients with latex allergy?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
Would you use TNF inhibitor therapy in a patient with seropositive RA who had optic neuritis as a child without relapse as an adult?
